Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles

@inproceedings{Cho2017ImmunotherapyFN,
  title={Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles},
  author={Ju Hwan Cho},
  booktitle={Immune network},
  year={2017}
}
Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Studies show that NSCLC is the more prevalent type of lung cancer that accounts for approximately 80%-85% of cases. Although, various treatment methods, such as chemotherapy, surgery, and radiation therapy have been used to treat lung cancer patients, there is an emergent need to develop more effective approaches to deal… CONTINUE READING
Tweets
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-5 of 5 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Phase II trial of autologous cancer vaccine , CG 8123 ( GVAX ) , in patients with advanced bronchioloalveolar carcinoma ( BAC ) : a Southwest Oncology Group Study ( S 0310 )

  • AM Davies, R Mudad, +6 authors DR Gandara
  • Curr Clin Pharmacol
  • 2017